#United States #Kirkland #Hepatitis D #EIT Pharma #Lonafarnib

EIT Pharma's FDA Milestone for Lonafarnib

EIT Pharma, Inc., a biotechnology company dedicated to developing treatments for infectious diseases, recently announced a significant achievement in its fight against chronic hepatitis D. The U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for lonafarnib, a groundbreaking oral therapy targeting one of the most serious forms of viral hepatitis.

Chronic hepatitis D (CHD) poses a considerable threat to millions of individuals worldwide. This severe liver disease, caused by the hepatitis D virus (HDV), is particularly dangerous for those already infected with hepatitis B. The progression of CHD can swiftly lead to dire consequences such as cirrhosis, liver failure, liver cancer, and ultimately, death. Surprisingly, despite its severity, effective treatment options have been remarkably limited in the United States, with no FDA-approved oral therapies currently available for CHD patients.

Dr. Leen Kawas, CEO of EIT Pharma, expressed the significance of the FDA's acceptance of their NDA, stating, "This is a critical milestone in our commitment to providing a new oral treatment option for people living with chronic hepatitis D. We are thankful to the patients and healthcare professionals who supported the D-LIVR study that made this achievement possible."

The Promise of Lonafarnib

Lonafarnib is an innovative, first-in-class investigational oral therapy candidate designed to address chronic hepatitis D. Its unique mechanism of action marks it as a pioneering candidate in late-stage clinical development, specifically for this condition. The therapy has already received notable designations from the FDA, including Breakthrough Therapy and Fast Track designations, demonstrating its potential significance in addressing an urgent medical need.

EIT Pharma acquired the late-stage lonafarnib program in 2024 and has been working diligently with regulatory bodies and medical experts to submit the NDA successfully. If approved, this oral medication could revolutionize treatment by providing patients with a user-friendly option that allows for room-temperature storage. This could be of paramount importance to those suffering from CHD, as it simplifies medication management compared to current treatment methods.

The NDA is backed by robust data from the Phase 3 D-LIVR study, which is the largest clinical trial conducted to date in the domain of chronic hepatitis D. This global, randomized, placebo-controlled study involved more than 400 participants across 21 countries, assessing the efficacy of lonafarnib over a span of 48 weeks.

Urgency for Novel Treatments

Dr. Jeffrey Glenn, co-founder of EIT Pharma and a respected professor at Stanford University, emphasized the critical need for innovative therapies in treating chronic hepatitis D. “The acceptance of our NDA is just the beginning as we strive to provide a new treatment option for this life-threatening disease,” he remarked. “Patients deserve access to novel therapies that specifically target critical steps in the hepatitis D virus lifecycle.”

As EIT Pharma moves forward, the company plans to maintain close collaboration with the FDA during the review process while simultaneously preparing for the potential commercialization of lonafarnib. The commitment to addressing the unmet medical needs of those afflicted by chronic hepatitis D remains a top priority for EIT Pharma.

In summary, the acceptance of lonafarnib's NDA by the FDA marks a pivotal point in the development of innovative treatments for chronic hepatitis D. As EIT Pharma navigates this critical phase, the hope for effective and accessible therapies for patients grappling with this challenging disease continues to grow.